Adipotide Peptide: A Comprehensive Guide to the Fat-Targeting Research Compound

Adipotide (FTPP) is a synthetic peptidomimetic compound developed to selectively target the blood vessels supplying white adipose tissue. It has been studied in preclinical research for its potential to induce targeted fat cell death through vascular ablation. This guide provides a detailed examination of the science, research findings, and practical considerations surrounding this compound.

Table of Contents

1. What is Adipotide?

2. Mechanism of Action

   • The Homing Peptide Domain

   • The Proapoptotic Effector Domain

   • Prohibitin as the Molecular Target

3. Research History and Development

4. What the Research Shows

   • Foundational Mouse Studies

   • The Rhesus Monkey Study

   • Nanoparticle Delivery Research

   • Exploratory Oncology Research

5. The Phase 1 Clinical Trial

6. Safety Profile and Kidney Toxicity Signal

7. Regulatory Status and Legal Considerations

8. Comparison with Other Obesity Research Approaches

9. Frequently Asked Questions

10. Conclusion

What is Adipotide?

Adipotide, also known as FTPP (Fat-Targeted Proapoptotic Peptide), is a synthetic peptidomimetic compound designed to selectively target the vasculature of white adipose tissue . It originated in the laboratory of Renata Pasqualini and Wadih Arap at the M.D. Anderson Cancer Center, with foundational work published in a 2004 Nature Medicine paper that used phage-display technology to screen for peptide sequences homing to white adipose vasculature in obese mice .

The compound is a bipartite molecule consisting of two functional domains joined by a short glycine linker:

• A targeting domain (CKGGRAKDC) that homes selectively to the inner surface of blood vessels feeding white adipose tissue

• A proapoptotic effector domain [D(KLAKLAK)₂] that disrupts mitochondrial membranes and triggers apoptosis 

The compound is not FDA-approved for any indication and has no approved compounding classification or legal pathway for human use in the United States as of 2026 . It has the PubChem CID 163360068 .

Mechanism of Action

The Homing Peptide Domain

The targeting module of Adipotide is a nine-amino-acid sequence (CKGGRAKDC) identified through phage-display screening. This sequence homes selectively to the vascular endothelium of white adipose tissue . The molecular receptor for this homing sequence is prohibitin, a protein enriched on the luminal endothelium of adipose vasculature .

Prohibitin functions as more than just a passive marker. Research published in JCI Insight (2016) and a 2022 diabetes paper demonstrated that endothelial prohibitin-1 mediates bidirectional long-chain fatty acid transport in white and brown adipose tissue . Its loss in endothelial cells suppresses glucose utilization under high-fat-diet conditions, helping explain why prohibitin expression is concentrated in these depots and why it represents a tractable molecular address for targeted interventions .

The Proapoptotic Effector Domain

The second segment, D(KLAKLAK)₂, is a proapoptotic effector. When delivered into a cell, this sequence disrupts mitochondrial membranes and triggers apoptosis through cytochrome c release . This mechanism was characterized in a 2001 Cancer Research paper by Mai, Mi, Kim, Ng, and Robbins, which showed that fusing a protein transduction domain to (KLAKLAK)₂ triggered rapid apoptosis across tumor cell lines and shrank established fibrosarcomas in mice .

Prohibitin as the Adipose Vascular Address

The selectivity of Adipotide depends on prohibitin’s expression pattern. Prohibitin is a multifunctional scaffold protein implicated in mitochondrial integrity, cell signaling, and transcriptional regulation . For Adipotide’s mechanism, the critical finding is that prohibitin is specifically enriched at the vascular endothelium of white adipose tissue in obese animals, giving the homing peptide its practical selectivity .

The complete mechanism works as follows:

1. The CKGGRAKDC domain binds to prohibitin on adipose vascular endothelium

2. The D(KLAKLAK)₂ payload is internalized by the target cell

3. Mitochondrial membranes are disrupted, triggering apoptosis

4. The blood vessels feeding that adipose depot are progressively ablated

5. Fat cells deprived of vascular supply undergo secondary cell death 

Because the targeting relies on a receptor whose surface expression is tied to the metabolic state of the tissue, the biology is more nuanced than a purely anatomical address .

Research History and Development

The development of Adipotide builds on several key scientific advances:

• 1999: A proof-of-concept paper by Ellerby, Arap, Ellerby, and colleagues demonstrated that a vascular-homing peptide could be coupled to a proapoptotic effector domain to kill targeted endothelial cells .

• 2002: Arap, Kolonin, Trepel, and colleagues formalized the phage-display methodology for mapping the human vasculature by peptide homing in a Nature Medicine paper .

• 2004: The foundational paper by Kolonin, Saha, Chan, Pasqualini, and Arap was published in Nature Medicine, describing the use of phage-display to identify the CKGGRAKDC sequence targeting white adipose vasculature .

• 2011: The most consequential study was published in Science Translational Medicine by Barnhart, Christianson, Hanley, and colleagues, showing weight loss in rhesus monkeys .

• 2012: Arrowhead Research Corporation announced dosing the first patient in a Phase 1 clinical trial for Adipotide® .

What the Research Shows

Foundational Mouse Study

In the 2004 Nature Medicine paper, investigators treated diet-induced obese mice with the Adipotide peptidomimetic and observed approximately 30% body weight reduction over 28 days of treatment. The reduction was attributed to apoptosis of adipose vascular endothelium and subsequent fat-cell resorption, not to changes in food intake per se .

A follow-on study by Kim, Woods, Seeley, and colleagues published in Diabetes (2010) treated diet-induced obese C57BL/6 mice with the peptide at 150 μg subcutaneously over 27 days. Key findings included :

• Significantly decreased cumulative energy intake and body weight in high-fat-diet-fed animals relative to vehicle controls (p < 0.05)

• Body weight of treated animals became statistically indistinguishable from lean low-fat-diet controls by day 27

• No conditioned taste aversion, indicating reduced intake was not an illness-like aversive response

The same group, reporting in Diabetes in 2012, found that the peptide produced rapid improvement in glucose tolerance in obese mice by days 2-3 of treatment, independent of weight and food intake changes (p < 0.05), alongside significantly reduced serum insulin and triglycerides (both p < 0.05) .

The Rhesus Monkey Study

The most consequential study of Adipotide was published in Science Translational Medicine in 2011 by Barnhart, Christianson, Hanley, and colleagues. This study enrolled spontaneously obese rhesus macaques (n = 10 treated, n = 5 controls) — a model that more closely approximates human obesity physiology than standard rodent models .

Key Findings :

• Weight loss: Approximately 10.6% of body weight over 28 days

• Fat reduction: 38% reduction in total body fat and 27% reduction in abdominal fat

• Insulin resistance: Significant improvement (p = 0.019)

• BMI and abdominal circumference: Significant reductions

• Dosing: 0.43 mg/kg subcutaneously daily for 28 days, followed by a 28-day recovery period

Important Finding: The same paper described mild, dose-dependent, reversible renal tubular degeneration and regeneration accompanied by elevated serum creatinine that normalized post-treatment . This safety signal would shape the compound’s subsequent development trajectory.

Nanoparticle Delivery Research

Follow-on work by Hossen, Kajimoto, Akita, Hyodo, and Harashima — published in the Journal of Controlled Release in 2012 and extended in 2013 — explored whether nanoparticle delivery of the D(KLAKLAK)₂ payload targeting CKGGRAKDC-bound endothelium could achieve comparable efficacy with a different toxicity profile .

Using PEGylated liposomes modified by PTP (prohibitin-targeting peptide), referred to as PTNP (prohibitin-targeted nanoparticle), researchers observed :

• Greater accumulation of particles in adipose endothelial cells

• Greater stability and potentiation of the peptide

• Weight gain in the group treated with the encapsulated peptide (at 3 times lower dose) was about 3 times lower compared to the group treated with the non-encapsulated peptide

• At the end of the experiment, mice treated with encapsulated peptide showed a 14% reduction from baseline body weight

• Reduction in serum leptin levels and increased serum adiponectin

• Potential to reduce ectopic fat content in liver and muscle tissue

Exploratory Oncology Research

The unique mechanism of Adipotide has led to exploration of its speculative implications in oncology. Research suggests the peptide’s potential to induce apoptosis in blood vessels might be relevant in studies focused on tumor vascularization . A 2009 Cancer Research paper by Zhang, Daquinag, Traktuev, and colleagues showed that white adipose tissue cells are recruited by experimental tumors, supporting the rationale for extending Adipotide-type platforms into oncology and cachexia research .

The Phase 1 Clinical Trial

On July 11, 2012, Arrowhead Research Corporation announced that the first patient had been dosed in a Phase 1 clinical trial with Adipotide® .

Trial Design :

• Population: Patients with castrate-resistant prostate cancer and no standard treatment options

• Duration: Single 28-day cycle of Adipotide

• Dosing: Injection under the skin once daily for 28 days

• Dose escalation: Up to five dose levels with three participants enrolled at each dose level

• Primary endpoint: Maximum tolerated dose

• Secondary endpoints: Pharmacokinetics, weight change, disease progression

Trial Rationale: Fat tissue is known to produce substances that can promote prostate cancer growth. Investigators at the M.D. Anderson Cancer Center sought to learn if decreasing white fat could slow the growth of prostate cancer .

Critical Limitation: No peer-reviewed published results from this trial have been produced as of April 2026 .

Safety Profile and Kidney Toxicity Signal

Observed Safety Signals

The most significant safety concern identified in research is dose-dependent renal tubular changes. In the rhesus monkey study, mild, dose-dependent, reversible renal tubular degeneration and regeneration was observed, accompanied by elevated serum creatinine that normalized post-treatment .

Preclinical Safety Data

• Animal studies: No systemic toxicity observed with daily dosing for one week in other studies

• Kidney concern: Dose-dependent renal tubular changes identified in non-human primates

• Reversibility: Changes appeared reversible post-treatment

Regulatory Limitations

• Not FDA-approved for human use

• No approved indication or compounding classification

• No legal pathway for human use in the United States 

• Not on the FDA’s 503A compoundable substances list 

Regulatory Status and Legal Considerations

Comparison with Other Obesity Research Approaches

A 2025 clinical trial for Pep19 demonstrated a 17 ± 4.7% reduction in visceral fat in obese adults over 60 days, with no reported adverse effects and improved sleep quality .

Frequently Asked Questions

What is Adipotide and how does it work?

Adipotide is a synthetic peptidomimetic compound that selectively targets the blood vessels supplying white adipose tissue. It consists of a homing domain (CKGGRAKDC) that binds to prohibitin on adipose vascular endothelium and a proapoptotic domain [D(KLAKLAK)₂] that disrupts mitochondrial membranes, triggering apoptosis of targeted endothelial cells. Fat cells deprived of their blood supply then undergo secondary cell death .

Is Adipotide FDA-approved?

No, Adipotide is not FDA-approved for any indication. It has no approved compounding classification and no legal pathway for human use in the United States as of April 2026 .

What does the research show about Adipotide?

Research demonstrates efficacy in animal models for weight loss and fat reduction. The most notable study (2011, Science Translational Medicine) showed obese rhesus monkeys lost approximately 10.6% of body weight over 28 days with a 38% reduction in total body fat . Mouse studies have shown up to 30% weight loss over 28 days . However, all research is preclinical with the exception of one announced but unpublished Phase 1 trial .

Are there any human studies on Adipotide?

A Phase 1 clinical trial was announced in July 2012, involving patients with castrate-resistant prostate cancer. The trial was designed to evaluate a single 28-day cycle of Adipotide. However, no peer-reviewed published results from this trial have been produced as of April 2026 .

What are the side effects of Adipotide?

The most significant safety concern identified in animal studies is dose-dependent renal tubular changes. In the rhesus monkey study, mild, reversible renal tubular degeneration and regeneration was observed, accompanied by elevated serum creatinine that normalized post-treatment . No human safety data has been published.

Why did Adipotide not advance further in development?

The kidney toxicity signal identified in the primate study likely influenced the development trajectory. Additionally, the absence of published results from the 2012 Phase 1 trial suggests the compound may not have met safety or efficacy endpoints, or the trial may have been discontinued. As of 2026, no further clinical development has been reported .

What is prohibitin and why is it important for Adipotide?

Prohibitin is a protein enriched on the luminal endothelium of adipose vasculature. It serves as the molecular receptor for Adipotide’s homing domain. Research shows endothelial prohibitin-1 mediates bidirectional long-chain fatty acid transport in adipose tissue, and its loss suppresses glucose utilization under high-fat-diet conditions .

Can I buy Adipotide for personal use?

Adipotide is not legally marketed for human use. As of April 2026, it is not on the FDA’s 503A compoundable substances list and there is no legal pathway for human use in the United States . Some gray-market research chemical vendors may offer it for research purposes only.

How was Adipotide discovered?

Adipotide originated in the laboratory of Renata Pasqualini and Wadih Arap at the M.D. Anderson Cancer Center. The foundational work used phage-display technology to screen for peptide sequences homing to white adipose vasculature in obese mice, leading to the identification of the CKGGRAKDC sequence .

Does Adipotide work by suppressing appetite?

No, Adipotide does not work by suppressing appetite or altering hunger hormones. Its mechanism is based on targeted fat tissue vascular ablation, offering an alternative pathway for metabolic support that does not involve appetite suppression .

Conclusion

Adipotide represents a conceptually innovative approach to targeted fat reduction through selective ablation of adipose vasculature. The compound demonstrated compelling efficacy in preclinical models, with obese rhesus monkeys losing an average of 10.6% of body weight and 38% of total body fat over 28 days of treatment . Its mechanism of action — targeting prohibitin on adipose vascular endothelium and triggering apoptosis — offered a novel alternative to appetite-suppressing approaches.

However, significant barriers have prevented Adipotide from advancing into clinical practice. The dose-dependent renal toxicity signal identified in primate studies raised important safety concerns, and no published results from the 2012 Phase 1 clinical trial have emerged as of 2026 . The compound’s regulatory status remains firmly in the research domain, with no FDA approval or legal pathway for human use .

For researchers, Adipotide remains an intriguing tool for studying adipose tissue biology, vascular targeting, and metabolic regulation. Its development history also serves as a cautionary tale about the challenges of translating promising preclinical findings into safe human therapeutics.